RP3
AXP000079.1 · Oncolytic virus
- Platform
- HSV-1 (RH018A strain, ICP34.5- ICP47-)
- Originator
- Replimune
- Sponsor
- Replimune
Names
| Name | Type | Source |
|---|---|---|
| RP3 ambiguous | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Strain
- RH018A
- Replication
- conditionally replicating
- Modifications
- RL1 (ICP34.5) and US12 (ICP47) deleted
- Transgenes
- CD40LG, TNFSF9, GALV-GP R-, anti-CTLA-4 antibody
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C179624
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Withdrawn | Phase 2 | 2024-01-30 | 2026-03-01 | 0 | Locally Advanced Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Terminated | Phase 2 | 2023-06-29 | 2025-08-18 | 5 | MSS; Refractory Metastatic Colorectal Cancer; pMMR |
| NCT04735978 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | Active not recruiting | Phase 1 | 2020-12-29 | 2026-11-30 | 123 | Advanced Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Notes
RP2 backbone with CD40L and 4-1BBL in place of GM-CSF, plus the anti-CTLA-4 molecule. First patient dosed in a phase 1 in 2021; phase 2 NCT05733611 terminated.
How to cite
RP3 (AXP000079.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000079.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.